ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

41 hedge funds and large institutions have $181M invested in Adaptimmune Therapeutics in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10: →

less funds holding

Funds holding: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less first-time investments, than exits

New positions opened: | Existing positions closed:

52% less capital invested

Capital invested by funds: $380M → $181M (-$198M)

Holders
41
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$7.42M
2
+$5.73M
3
+$3.05M
4
Jennison Associates
Jennison Associates
New York
+$1.62M
5
IHM
Iguana Healthcare Management
New York
+$898K

Top Sellers

1
-$50.7M
2
-$16.1M
3
-$8.78M
4
FCM
Farallon Capital Management
California
-$4.58M
5
NHAS
Novo Holdings A/S
Denmark
-$4.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$287K
27
$218K
28
$192K
29
$172K
30
$126K
31
$120K
32
$84K
33
$62K
34
$62K
35
$30K
36
$29K
37
$22K
38
$18K
39
$12K
40
$7K
41
$2K
42
–
43
–
44
–
45
–
46
–
47
–
48
–
49
–
50
–
1
2
3